新型国产BuMA支架在急性冠脉综合征的应用研究

Research on the application of new domestic BuMA drug-eluting stent in patients with acute coronary syndrome

目的比较国产BuMA支架和进口XienceⅤ支架在急性冠脉综合征应用的有效性和安全性。方法将116例急性冠脉综合征患者随机分为BuMA支架组和XienceⅤ支架组,每组58例,平均随访9个月,观察冠状动脉造影情况和主要心血管事件发生率。结果 BuMA支架组再发心绞痛、非致死性心肌梗死、再次血运重建、支架血栓和再狭窄的发生率分别为5.2%、1.7%、3.4%、2.2%和6.7%,而在XienceⅤ支架组分别为6.9%、1.7%、3.4%、2.4%和7.3%,差异无统计学意义(P>0.05)。两组均无死亡病例。结论与进口XienceⅤ支架相似,国产BuMA支架在急性冠脉综合征患者中的应用是安全、有效的。

Objective To compare the efficacy and safety of domestic BuMA stent with imported Xience V stent for acute coronary syndrome （ACS）. Methods 116 patients with ACS were randomized to BuMA （ n = 58 ） and Xience V （ n = 58 ） groups. During 9 months follow-up, coronary angiographic outcome and major adverse cardiac events were observed. Results The ratio of recurrent angina pectoris, non-fatal myocardial infarction, revascularization, in-stent thrombosis and restenosis were 5.2%, 1.7%, 3.4% ,2. 2% and 6. 7% respectively in the BuMA group vs. 6. 9%, 1.7%, 3.4%, 2.4% and 7. 3% respectively in the Xience V group （P 〉 0. 05 ）. There was no death in both groups. Conclusions Similar to the Xience V stent, application of domestic BuMA stent for acute coronary syndrome is safe and effective.